Maikokang Biotechnology

Maikokang Biotechnology (Maxvax) is a clinical-stage biopharmaceutical company headquartered in Chengdu, China, specializing in the development of innovative vaccines and proprietary adjuvant technologies. The company leverages its dual-platform approach—combining novel adjuvants with recombinant protein antigens—to create high-efficacy vaccines for infectious diseases and cancer. Its lead candidate, MAV-001, is a recombinant herpes zoster vaccine currently in Phase 2 clinical trials, aiming to provide a potent alternative to existing global products. Maikokang's pipeline also includes a trivalent rotavirus vaccine and candidates for HPV and COVID-19. With integrated R&D and large-scale GMP manufacturing facilities, the company is positioned to address significant public health challenges both in China and internationally.